Image source: The Motley Fool.
Tuesday, Nov. 17, 2026
Need a quote from a Motley Fool analyst? Email pr@fool.com
NRx (NASDAQ:NRXP) reported a transition from a clinical-stage firm to a commercial biopharmaceutical company following the first FDA approval of its preservative-free ketamine product. Management stated the company restructured into four distinct divisions: NeuroRx Pharmaceuticals, HOPE Therapeutics, NRx Defense Systems, and GeNeuro. The company reported the elimination of all convertible debt and the acquisition of clinical revenue streams through its HOPE clinics. CEO Javitt noted that the recent FDA approval of the blow-fill-seal packaging platform offers a cost-effective alternative to traditional glass bottling, aiming to address national security concerns regarding the sterile injectable supply chain.
Operator: Good day, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Third Quarter 2026 Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Brian Korb of Astr partners. Please go ahead.
Brian Korb: Thank you, operator, and good morning, everyone. Joining me on today's call are Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer; and Michael Abrams, Chief Financial Officer of NRx Pharmaceuticals. Following their prepared remarks, we'll open the call for questions. Yesterday, NRx filed its quarterly report on Form 10-Q for the quarter ended September 30, 2026, with the Securities and Exchange Commission. The 10-Q is available on the Investors section of the company's website and on the SEC's website. Before we begin, please note that statements made on this call that are not historical facts are forward-looking statements.
Actual results may differ materially due to risks and uncertainties, including those described in the Risk Factors section of our most recent Form 10-K and subsequent filings with the SEC. I'm now pleased to turn the call over to Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals. Jonathan, go ahead.
Jonathan Javitt: Thank you, Brian. Good morning, and thank you for attending our third quarter conference call. The third quarter of 2026 has been the quarter in which seeds that were planted 2 years ago have begun to grow into a sustainable orchard. As you recall, exactly 2 years ago, we announced the resignation of the company's former management and the Board's recognition that we needed to chart a new path forward. The company at that time had no near-term path to an approved drug. It was paralyzed by toxic debt and lacked a strategic direction. Our market capitalization was $15 million, and the company reported $1.6 million in cash at the end of the quarter.
Two years later, we've shed all the convertible debt from our balance sheet. We've attracted healthcare specialists and institutional investors led by the B Group who provided us with a path to profitability. We've been granted our first FDA drug approval. We have a 17-person veteran sales force led by a seasoned commercial team engaging customers every day, one of whom gave us our first order yesterday. Our market capitalization is approximately $95 million and has reached twice that in the past 6 months. We ended our third quarter with about $20 million in cash and cash equivalents. We have clinics that are generating revenue.
We have earned the trust of the Defense Advanced Research Projects Agency, and we've been tasked with leading the clinical development of their most promising solution to treating depression and PTSD in the military. We are gearing up for a commercially successful 2027 in which we aim to demonstrate a path to profitability, and we have an early-stage opportunity that may lead to the world's first disease-modifying drugs for ALS and schizophrenia in partnership with the U.S. National Institutes of Health and the governments of France and Switzerland. A recurring theme that we hear from shareholders is the feeling that they've been diluted over the past 2 years as we built a new, hopefully durable and potentially near-term profitable company.
In reality, management believes that the owners of approximately 11 million shares that were outstanding in September 2024 today own about 65% more value 2 years later based on their proportionate share in our current enterprise. Over the same period, the S&P 500 increased half that amount, 31%. While today's equity market is challenging for all biotechnology stocks, we hope that going forward, it will be less challenging for companies like ours that are actively booking revenue and earning profits than for companies that are still years away from a first drug approval. Over the 2 years since we changed our management team and became a working board building a working company, we've undergone extraordinary change in structure and focus.
The quarterly report that we filed yesterday is far longer than usual, and we hope you will read the business description carefully to better understand who we have become. We anticipate that the business structure we've laid out will be the structure by which we operate NRx for the foreseeable future. As outlined in the business description, we now have 4 divisions, each intended to be financed through mechanisms that are potentially nondilutive to NRXP shareholders and more importantly, each of which has near-term opportunity to become a profitable enterprise in its own right. We believe each of these has potential to return considerable value to those who own NRXP stock.
In brief, those divisions are: 1, our core NRx Pharmaceuticals company, which has expanded its focus from drugs that affect the central nervous system in depression and suicidality to encompass a promising sterile injectable products initiative; 2, our HOPE Therapeutics clinical division in which we treat patients with those CNS conditions; 3, NRx Defense Systems, which just signed its first prime contract with the Department of War; and 4, GeNeuro Incorporated, which has the potential to deliver the world's first disease-modifying drugs for ALS and schizophrenia.
NRx Pharmaceuticals was the original basis of -- sorry, NeuroRx Pharmaceuticals was the original basis of NRx Pharmaceuticals, focused on the development of an innovative drug to treat bipolar depression, the drug we call NRX-101. NeuroRx has now expanded to encompass not only its foundation drug, but a new sterile injectable products division that has just been granted its first drug approval. So the aim of NeuroRx sterile products is to deliver sterile injectable products at margins that are consistent with the margins for innovative drugs.
A key focus of our plan was to concentrate on immediately revenue-generating drugs such as preservative-free ketamine that could provide a solid financial foundation to our company as we seek to bring even more valuable innovative drugs to the market. As you know, Chaim Hurvitz, former President of Teva International, is one of our founding investors and Board members. Chaim and I learned a great deal from his father, Eli Hurvitz and later from Dr. Phillip Frost and the manner in which Teva built a solid foundation in immediately profitable generic drugs and then supported the extraordinary success of COPAXONE and successor innovative drugs. When we founded the company, we did not set out to sell sterile injectable drugs.
It was a byproduct of the FDA advising us in January 2023 that if we expected to use ketamine in conjunction with NRX-101, we would need to add psychiatry claims to generic ketamine. In working to satisfy that requirement, we discovered that the entire ketamine drug supply chain in the United States was broken. It had moved overseas and Americans were threatened by chronic shortage of ketamine and other sterile injectable products. We realized the critical need for sterile injectable drugs that could be manufactured in the United States at low cost and with minimal regulatory risk.
We estimate the current United States demand for sterile injectable ketamine alone at approximately $400 million a year and to be growing at more than 17% a year as ketamine is increasingly used in hospitals for pain control as well as anesthesia. This estimate does not fully incorporate the potential of ketamine to be used in treatment of depression and PTSD under our NRX-100 program. If we add a few similar sterile products, NRx can double or triple its currently addressable market in early 2027. The entire U.S. generic sterile products market is estimated at $23 billion according to IMARC. That's just generic drugs. It doesn't count the branded drugs.
Congressional and executive branch leaders have recognized the urgent national security need to bring the manufacture of strategic drugs back within the borders of the U.S. We're in active discussions with those leaders on both sides of the political aisle. In the post-COVID years, while nobody was looking, our sterile injectable supply chain became unstable to the point where 10% to 20% of those drugs are now supplied by compounding pharmacies for lack of an FDA-approved drug. FDA is actively engaged in enforcement actions that highlight the risks of compounding and FDA is forcing many compounders out of business. Moreover, 503B compounded drugs may not be legally sold when an FDA-approved drug is available and not in drug shortage.
This creates an urgent need and a growing opportunity for NRx's sterile injectable solutions. The real problem with these drugs is not the sterile drug, it's the glass bottle. During our COVID experience with ZYESAMI, we learned that the cost of bottling a drug in glass is about $3.25 a unit. The cost is driven not only by the cost of the glass, but also by the relatively low volume and high labor intensity of a sterile glass bottling line. Ask yourself, when is the last time you saw a glass milk bottle in the grocery store unless it was a boutique product.
Until now, injectable drugs could not be manufactured in more economical blow-fill-seal packaging because there was no FDA-approved mechanism to transfer the medication from the BFS container to a sterile syringe in a manner that medication could be withdrawn from a glass vial. We worked with our partner, Nephron Pharmaceuticals and our German equipment manufacturer to solve that problem using a Luer-Lock drug device combination now approved as part of NRx's abbreviated new drug application by the FDA on October 29, 2026, for preservative-free ketamine product. Although the Luer-Lock was previously incorporated in a grandfathered water for injection product, this was the first drug approval in which a blow-fill-seal vial was approved by FDA as a drug device combination.
This innovation, which required hundreds of pages of regulatory documentation and engineering testing will provide NRx with a market-leading platform for this and future sterile injectable drugs. Competitors will surely follow, but we predict it will take them considerable engineering time to stand up the manufacturing lines and then years of stability testing to get to the point where they can compete with us in the market. This manufacturing breakthrough has led to a cost of goods or COGS that's a fraction of the former cost of glass vial packaged drugs. For instance, 900,000 blow-fill-seal units can be manufactured on a BFS manufacturing line in the same time as 50,000 glass bottles can be filled, stoppered, crimp-capped, and packaged.
Compared with the roughly $3.25 per unit we saw with glass, we anticipate our COGS with BFS is approximately $0.75 a unit. The cost of buying and managing the glass generally exceeds the cost of the active pharmaceutical ingredient. This high COGS may help explain the diminished supply of sterile injectable products from overseas. It's at the point where the glass bottle manufacturers just have no margin left in their products. The innovative packaging of our first approved products also benefits the hospital personnel who handle it.
When pharmacists, nurses and doctors draw injectable products from a traditional glass vial, they first have to mount the needle on a syringe, pierce a rubber stopper with that needle and safely dispose of the needle. CDC estimates that hospital-based healthcare personnel in the United States report approximately 385,000 needle stick and other sharps injuries a year, a figure that is probably half of the true burden. In addition, the NRx Luer vial does not generate sharps medical waste, which is costly and complex to dispose of. Staff safety and staff time are at a premium in every U.S. hospitals and customers have applauded the value of the NRx BFS solution.
NRx human factor studies have demonstrated considerable time savings for medical staff with the Luer-Lock vial compared to traditional glass bottles and very high user satisfaction. The aim of our Innovative Pharmaceuticals division, on the other hand, is to develop NMDA antagonist drugs to treat depression and suicidality. As shareholders, you're well aware of our focus in obtaining FDA approval for ketamine to treat depression and suicidality. We plan to submit a new drug application for ketamine in the second quarter of this year when FDA granted us Fast Track designation. In the subsequent months, we've worked iteratively with FDA to solve several regulatory challenges and hope to submit a rolling NDA by the end of this year.
First of all, we had to solve the Luer-lock challenge that FDA raised in the context of our ANDA. As you know, it's now solved. Second, FDA asked us to document that the PHQ-9 depression scale used in most real-world evidence was comparable to the Montgomery-Åsberg Depression scale used in most clinical trials. We asked our partners at Yale University to address this challenge, and we've reproduced a sample of that comparative data in the 10-Q filed yesterday for you to read. Third, we decided to embark on a dual path to ketamine approval, seeking both regular approval and accelerated approval.
For regular approval, we will be submitting more than 500 patients of randomized clinical trial data and 65,000 patients of real-world evidence. Please familiarize yourself with the online guidance that FDA publishes under accelerated approval. Under that pathway, a sponsor can submit evidence that documents the effectiveness of a drug in achieving an intermediate clinical endpoint, such as short-term remission from depression and/or suicidality. In that pathway, the sponsor is able to obtain immediate approval to market a drug with the requirement that confirmatory evidence of long-term benefit will be delivered to FDA within 5 years.
That's why we're delighted to announce that we've now signed a collaboration agreement with Yale University and with the written approval of the PCORI or Patient-Centered Outcomes Research Institute, a government-funded initiative for NRx to join as the sponsor of a newly launched PCORI study that will compare IV ketamine to intranasal S-ketamine. We're confident that this 5-year study will provide the confirmatory data that the accelerated approval guidelines require and thus qualify us for accelerated approval. Whether by accelerated approval or regular approval, we believe NRX-100 can be approved in 2027. As you know, our company began with NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone to treat suicidal bipolar depression.
That drug was awarded breakthrough therapy designation by the FDA and was shown to reduce depression, suicidality and akathisia in 2 randomized controlled trials, where it demonstrated superiority to lurasidone, a standard of care drug for bipolar depression in relieving symptoms of akathisia and suicidality. Despite the effectiveness of NRX-101 in this indication, the future of twice-daily pills as a standard of care for treating depression is rapidly being challenged by interventional psychiatry advances in which our company is actively engaged. The unexpected positive development for NRX-101 was the discovery that the ingredients of NRX-101 could significantly augment the effectiveness of Transcranial Magnetic Stimulation, or TMS, and potentially enable a rapid 1-day treatment of depression with durable results.
In September 2026, the Defense Advanced Research Projects Agency, or DARPA, awarded NRx Defense Systems, a prime contract to lead the SPARC-TMS trial, a Phase 2/3 clinical trial that has potential to support an FDA approval for NRX-101 in conjunction with rapid robotic Transcranial Magnetic Stimulation. The company is finalizing a cooperative research and development agreement with the Uniformed Services University of the Health Sciences to expand this trial to several leading military hospitals. Between the currently funded SPARC-TMS trial and the planned military hospital arm, more than 400 patients are expected to be enrolled and treated in 2027. The SPARC-TMS trial is scheduled to read out in early 2028.
A positive readout could support approval of NRX-101 with clinical trial costs funded by the Department of War as opposed to continued dilutive shareholder raises. We have a new pipeline product to announce today, NRX-200. Through our experience at HOPE Therapeutics, we've increasingly recognized the ergonomic challenges of administering IV ketamine to treat depression. IV infusion of ketamine, if it's done in compliance with laws found in most states, requires infusion nurses, nurse anesthetists, anesthesiologists who are similar highly trained personnel. Oral intramuscular and intranasal forms of ketamine are believed by many to be less efficacious in treating depression.
A steady state of low-dose ketamine is optimal to achieve the antidepressant effect, which cannot be achieved through any of the above routes. An ideal route of administration might be subcutaneous ketamine, which can be delivered by an insulin type pump with no IV needles or IV setup. The barrier to subcutaneous ketamine is that ketamine hydrochloride, the currently used form of the drug is highly acidic and barred from subcutaneous infusion. Any attempt to raise the pH of ketamine hydrochloride with standard buffers results in its precipitation from solution.
NRx has developed and demonstrated the feasibility of a proprietary formulation of ketamine based on an already FDA-approved cyclodextrin vehicle, which is exclusively licensed to NRx and for this purpose and which has a neutral pH. Should this subcutaneous approach prove successful, we believe that it could become the standard of care for administration of ketamine to treat depression and offer advantages over either intranasal or intravenous ketamine while providing NRx with long-term IP protection on this formulation because the vehicle itself is proprietary. NRX-200 will enter pharmacokinetic testing in early 2027. A first-in-human clinical trial is targeted for September 2027.
This trial will be conducted at HOPE Therapeutics, where our per patient costs are controlled and where we have direct quality oversight. In the first few years, there has been a sea change from traditional antidepressants to combined neuroplastic care. While SSRI and SNRI oral medications remain the most commonly used treatments, their complications are well known, including their risk of inducing suicidal ideation. NMDA antagonist drugs, psychedelic drugs and Transcranial Magnetic Stimulation have advanced. We presented a comparison of the reported effects at the 2026 Cantor Fitzgerald Healthcare Conference, and that comparison is also included as an illustration in the 10-Q. I hope you look at it.
While we're far from a standard of care treatment that will replace traditional oral antidepressants, we believe the efficacy reported in the most successful clinical trials of psychedelic drugs does not exceed the efficacy of traditional antidepressants, although the psychedelic drugs are generally administered on one or several occasions rather than several times a day. Intravenous ketamine effectiveness has been reported in multiple clinical trials to exceed that of oral antidepressants, although the question of whether IV ketamine can be used as a chronic treatment because of its potential for addiction and neurotoxicity remains an open question.
These reported data underlie the enthusiasm for exploring a 1-day or short-term treatment with focused Transcranial Magnetic Stimulation, especially among military personnel and first responders for whom traditional oral antidepressants and newer psychedelic medications are incompatible with continued military service. This recognition underlies DARPA's STRENGTHEN program and the SPARC-TMS clinical trial. We've put links to those programs in the 10-Q, and we hope you'll look at them. This also shapes our focus at HOPE Therapeutics. During 2025, we developed the operating model for HOPE and made initial clinic acquisitions with funding from the B Group.
HOPE generated its first clinical revenue in Q4 '25 and as of September 30, 2026, operates in 6 locations in Florida, including Dura Medical, Cohen and Associates and clinics founded by HOPE. We originally expected to incur additional debt and to lead a clinic roll-up. As we learn more, however, we saw roll-up failing all over the country and recognize the need for better technology HOPE is moving powerfully and deliberately to be at the forefront of that technology. We partnered with Zeta Surgical of Boston to implement the first robotic neuronavigated TMS and to treat the first patients with this technology advance.
In the preamble to the DARPA contract, the Department of War states that success in the SPARC-TMS project has potential to set standard of care for treating depression in the military and first responders. During 2026, NRx founded NRx Defense Systems, which we call NRXd as a fully qualified military contractor in response to DARPA's invitation to bid their broad agency announcement. NRXd focuses on military and first responder uses of NRx [ Hope ] technology in partnership with DARPA, the Uniformed Services University of the Health Sciences, the Walter Reed National Military Medical Center, the Henry M. Jackson Foundation and first responder organizations.
NRxD's $11.2 million initial prime contract from DARPA for the SPARC-TMS clinical trial is a lead component of the STRENGTHEN program focused on treating depression, PTSD and suicidality in the military. We're partnered with Harvard Medical School's McLean Hospital and Arizona State University in the conduct of this trial. More importantly for shareholders, however, you now own a fully qualified DARPA contractor that meets the security and cybersecurity of current and future defense contracts. NRxD has been advised by DARPA that it satisfied its initial milestones and the first 2 invoices are approved for payment in Q4 2026. We anticipate achieving other milestones and other funding during that same quarter.
NRxD is anticipated to be funded through nondilutive capital to make a profit and to yield a modest contribution margin to the NRx parent company. We aim to have NRxD become an increasingly profitable component of NRx as additional opportunities arise to deploy our technology to serve patients in the military and in other governmental avenues who have depression, PTSD and suicidality. Finally, let's talk for a few moments about GeNeuro, whose aim is to develop the first disease-modifying drugs for ALS and schizophrenia. The 10-Q explains how human endogenous retroviruses entered the human genome more than 100,000 years ago.
Because this is such a new area of science and because it's something that most people have never heard of, we hope you'll take time to familiarize yourself with what's going on. The viral DNA that entered our genome through those endogenous retroviruses or HERVs has remained with us as part of the dark genome. When I got my biochemistry degree in 1978, they taught me that 8% of the human genome was junk DNA. We now know that, that 8% is actually the remnants of these old HERVs that entered the genome and stayed in our genome.
However, when parts of those ancient viruses are activated by various stimuli, could be environmental stimuli, could be a viral infection, could be trauma, neurodegenerative diseases, including ALS and schizophrenia may result. The GeNeuro assets were purchased in a Swiss bankruptcy auction after the failure of a Swiss biotechnology company that suffered from decisions to focus on clinical trial targets such as Long COVID rather than the core targets that we've described. That company never had the chance to develop its extraordinary discovery together with the U.S.
National Institutes of Health the discovery that HERV-K envelope protein may cause ALS and that an antibody to this toxic protein, which we call GNK-301 may enable patients with ALS to survive and even thrive. Please read the detail in our 10-Q and watch the keynote talk I recently gave at the Sachs Biotechnology Forum in Basel, if you want to understand this breakthrough. Not only does GeNeuro have a potentially disease-modifying drug for ALS, it has an antibody that has already been tested in multiple human trials called Temelimab, which we now intend to test for schizophrenia. We plan to hold a Science Day to explain GeNeuro's science during the first week in December.
Funds for GeNeuro are anticipated to come from government and private investors. NRx will own enough of GeNeuro that if GeNeuro succeeds, the value of this component to NRx's balance sheet might eclipse the rest of NRx. At the same time, we expect NRx to become profitable from the products I've described above, and GeNeuro is expected to be largely financed through mechanisms that do not dilute NRxP shareholders. There's far more going on with GeNeuro that can be addressed in this quarterly conference call, and we look forward to continuing to share our progress and to tell you about future opportunities to invest in GeNeuro. With that, I'll turn the call over to Michael Abrams, our Chief Financial Officer.
Michael Abrams: Thank you, Jonathan. For the third quarter ended September 30, 2026, NRx reported net patient revenue of $1.2 million compared with $0.2 million for the third quarter of 2025. Loss from operations was $8.1 million compared with $4 million from the prior quarter and a net loss of $2.2 million or $0.05 per share compared with a net loss of $5.9 million or $0.27 per share for the prior comparable quarter. For the 9 months ended September 30, 2026, NRx reported a net loss of $20.1 million versus a net loss of $29 million during the comparable period of 2025.
The change is primarily related to the impact of certain fair value accounting measurements and other nonrecurring charges related to the conversion and restructuring of previously issued convertible notes incurred during the 9 months ended September 30, 2025, which were partially offset by an increase in operating expense during the current period. For the 9 months ended September 30, 2026, NRx reported a loss from operations of $19.4 million versus a loss of operations of $11.6 million for the comparable period in 2025.
This change was driven by several factors, including: 1, an increase in cost of services from higher revenue generated at our HOPE clinics; 2, an increase in research and development expense related to the advancement of our various drug development initiatives; and 3, an increase in selling, general and administrative costs related to the commercial launch of our first approved drug for preservative-free IV ketamine. As of September 30, 2026, the company had approximately $19.8 million in cash and cash equivalents versus $7.8 million as of December 31, 2025. The increase is primarily related to the company's completion of a public offering of common stock with gross proceeds of more than $22 million.
Management believes current cash resources, revenue from the recent launch of the company's first approved drug, planned growth in clinic revenue at our HOPE clinics and opportunistic utilization of the company's active at-the-market offering facility will be sufficient to support operations for the foreseeable future. With that, I turn the call back over to Jonathan.
Jonathan Javitt: Thank you, Michael. It's been an extraordinary 2 years. To summarize, the third quarter and the weeks since have marked NRx's transition from a development stage company to a commercial pharmaceutical company. On October 29, FDA approved our abbreviated new drug application for preservative-free ketamine, our first drug approval and the first approval of a blow-fill-seal Luer-Lock vial as a drug device combination that will serve as a platform for a rapidly growing stable of sterile injectable products at a time when the United States desperately needs that capacity. Our 17-person veteran sales force is now in the field, and we received our first order yesterday.
We ended the quarter with approximately $20 million in cash and cash equivalents and no convertible debt on our balance sheet. Each of our 4 divisions is advancing. At NeuroRx, we aim to submit a rolling new drug application for NRX-100 by the end of this year and with our Yale collaboration supporting the accelerated approval pathway and NRX-200, our new subcutaneous ketamine formulation is expected to enter pharmacokinetic testing in early 2027. HOPE Therapeutics now operates 6 locations in Florida, is actively generating a growing amount of clinical revenue and is treating patients with robotic neuronavigated TMS.
NRx Defense Systems has just earned its first milestone payments from the Defense Advanced Research Projects Agency and is leading the DARPA-funded SPARC-TMS trial of NRX-101. At GeNeuro, we plan to hold a Science Day during the first week of December to share with you the breakthrough importance of this technology. Our goal for 2027 is to build a commercially successful company that demonstrates profitability while funding our innovation for nondilutive sources whenever possible. With that, operator, please open the line for questions.
Operator: [Operator Instructions] The first question comes from Elemer Piros from Lucid Capital Markets.
Elemer Piros: So several questions. The preservative-free ketamine, which you used to call KETAFREE, does that have a name, a new name or you stay with KETAFREE?
Jonathan Javitt: Right now, the label says ketamine preservative-free and customers are telling us that they like having a label that says exactly what the drug is. We continue to talk about adding a trade name. But right now, the customers like the clarity.
Elemer Piros: Okay. And with the newly announced NRX-200 program, the subcu formulation, when you go into a first-in-human trial other than the PK study, what is the plan there to show what sort of parameters for bioequivalence or what sort of trial are you envisioning there?
Jonathan Javitt: Well, we expect that NRX-200 delivered through a subcutaneous pump like an insulin pump will certainly be non-inferior to intranasal ketamine, will be equivalent to intravenous ketamine and will be superior to placebo. So we'll design a trial right around that. And it wouldn't surprise me if it mirrors what's going on in the PCORI study, where we're demonstrating non-inferiority of IV ketamine to SPRAVATO.
Elemer Piros: And so would NRX-100 and NRX-200 be complementary products on the market?
Jonathan Javitt: NRX-100 will have a period of data exclusivity that's measured in single-digit years because it's a new use for a generic drug, where NRX-200 will have almost an infinite period of exclusivity because the cyclodextrin vehicle has an ingredient composition that's about as secret as Coca-Cola. So how we'll dovetail those products is going to be a commercial decision, but I think you know us well enough to know that we'll do it cleverly.
Elemer Piros: Right. And the study with Yale, a 5-year study, is it 5 years to -- from start to finish or it's a 5-year observation of patients? If you could clarify that?
Jonathan Javitt: Well, the PCORI study is intended to have a readout within 5 years, which is well within the FDA requirement to submit confirmatory data of an accelerated approval within 5 years. So it basically gives us 2 ways to get NRX-100 approved, either FDA will decide that our real-world evidence is sufficient for regular approval or it's -- we believe it's certainly sufficient for accelerated approval with the PCORI data being submitted as the confirmatory information at the end of 5 years.
Elemer Piros: Okay. And my last question is, what is the order of magnitude of your first order for preservative-free ketamine?
Jonathan Javitt: We're going to announce something about what we've received over the course of the quarter as soon as the quarter ends.
Operator: The next question comes from Patrick Trucchio with H.C. Wainwright.
Patrick Trucchio: Congrats on all the progress. I was wondering how you envision ketamine sort of expanding in the market, if you envision sort of as the interventional psychiatry infrastructure continues to expand, should we expect sort of that rollout to expand with the infrastructure? And how much actual share do you think you could take from competing products in the market?
Jonathan Javitt: Well, if what you're talking about is preservative-free ketamine, the primary market for preservative-free ketamine is not psychiatry clinics. The primary market for preservative-free ketamine is hospitals and hospital outpatient departments where it's used for anesthesia and pain control in large quantities. That market is about $400 million a year, and it's growing -- seems to be growing by about 17% a year. We believe that customers like our product. They find the innovative packaging easier to use, safer for their staff, more efficient for their staff. And the real game changer will be how the preservative-free aspect is received. Customers like the idea of preservative-free. Consumers like it even better.
But if the government grants our citizen petition because we've shown the government that ketamine with benzethonium chloride is being used at toxic levels or at least at levels that exceed the government's toxicity threshold in hospitals every day, we have the potential for a market-clearing event. We're not saying that's going to happen. We'll be very happy if we take 20%, 30% of the market just by being better at what we do, having more innovative packaging, having a product that staff and patients like better.
But if we get that citizen petition, and it's certainly consistent with everything Secretary Kennedy has said about his determination to get toxic preservatives out of the food chain, out of the supply of drugs. If we get that, all of a sudden, we have a potential market-clearing event. What we really have to do is demonstrate that we can supply the whole U.S. market without a risk of a drug shortage. And given our ability to manufacture 900,000 doses per batch, that's basically an ability to make 4 million or 5 million units a month. That's enough to supply the whole United States. So obviously, we're going to shoot for the moon.
But if all we do is hit some singles and doubles, anybody who saw Moneyball knows that's a worthwhile objective.
Patrick Trucchio: That's really helpful. And understanding that we'll have more details on the ALS opportunity in December. I'm wondering how you ultimately envision GNK-301 as a treatment for a broad ALS population? Or would it be sort of more for a biologically defined subgroup? And how does that distinction -- how will that shape your development strategy ultimately?
Jonathan Javitt: Pat, that's a wonderful question, and I hope that you're going to be very involved in producing our Science Day. So the answer to your question is yes. It's targeted for a biologically defined subgroup. However, that biologically defined subgroup is the vast majority of people who have ALS. So all of this is work that's been done by GeNeuro in partnership with Professor Avi Nath, who is the Head of ALS at the U.S. National Institutes of Health. It's all in peer-reviewed publications, been reviewed by the nation's top scientists. And what we know -- and this is really brand-new science, but it's breathtaking science.
What we know is that 70% of people being seen at the National Institutes of Health with ALS have the envelope protein for endogenous retrovirus K in their cerebrospinal fluid in the fluid that surrounds the brain. And this envelope protein is highly neurotoxic. If you take the CSF from a patient with ALS and put it in a mouse, it gives ALS to the mouse. If you take that CSF and put it in human motor neuron cell culture, it kills the motor neuron cells in the same way that ALS does. And if you take our antibody, GNK-301 and add it to that system, you block the toxic effect.
So this is an area of science that I was involved in 25 years ago when we developed the first drugs for macular degeneration. To this day, nobody knows why VEGF, vascular endothelial growth factor is made in the retina of people with macular degeneration. And that toxic protein causes the retina to grow new blood vessels and make people go blind. To this day, nobody has ever been able to turn off VEGF production. But ever since 2004, we've had antibodies that soak up that VEGF. I was involved in Macugen. The most successful one in that early time was LUCENTIS or Avastin antibodies that soak up the toxic protein and prevent people from going blind. Same thing here.
Now that we've identified the toxic protein, which is the HERV-K envelope protein, we have an antibody that soaks it up just like a sponge soaks up spilled milk. And all of the animal work that's been done so far suggests that, that antibody can block the toxic effects of HERV-K envelope protein in people with ALS. So to go back to your question, does this work for a subgroup? Yes, it works for a subgroup. It works for a subgroup that we can identify just with a test for HERV-K envelope protein in the spinal tap or probably in the blood. And yes, that subgroup just happens to be almost everybody with ALS.
Operator: The next question comes from Tom Shrader with BTIG.
Thomas Shrader: I have some questions kind of clerical in nature. The 101 trial in TMS, is that going to be pure 101 or D-cycloserine? And just your thoughts on the lurasidone component? Is it -- just -- we know a lot about D-cycloserine in TMS. I don't think we know a lot about lurasidone. So maybe just an update on -- does that change anything in your mind? Or should we continue to look at D-cycloserine as the sort of comparator? And then I have a couple of follow-ups.
Jonathan Javitt: The trial that's funded by DARPA, the trial that is described in clinicaltrials.gov, the trial that's been approved by the FDA to proceed with patient enrollment uses NRX-101 exactly as you know it at a low dose. It's 175 milligrams of D-cycloserine, and I believe 7.5 milligrams of lurasidone, which is a pill that we already make. It's sitting in our warehouse. We have the matching placebo. It's ready to go into patients. There are data that have been developed over the last couple of months, suggesting that the lurasidone component does make a meaningful beneficial contribution in addition to the D-cycloserine. And you should expect those data to be published by our scientific colleagues at Harvard.
Thomas Shrader: Okay. And then the NRX-100, when you got Fast Track designation, at least you reported submitting data with that, which is something -- is that unusual for Fast Track? I usually think of data as being for breakthrough. And it sounds like you had -- how much have they looked at your trials? It sounds like from your comments that they have commented on the endpoint. I'm really getting at the NRX-100 NDA, is it partially reviewed as part of Fast Track? How much have they seen? And how much do you think is already accepted as the kind of package they're looking for?
Jonathan Javitt: Well, I wouldn't ever want to comment on what the FDA has already accepted, but you're asking a great question. So first of all, I don't know what other divisions of FDA do, but I can tell you that the psychiatry division is pretty rigorous about Fast Track, and they don't award Fast Track for a clinical-stage drug without looking at data. Yes, there are some Fast Track designations that get approved at preclinical stages without data, but those are for earlier-stage drugs. So yes, they looked at our data. They've looked at our data in a great amount of detail. They've looked at the clinical trials data.
And as we pointed out, they looked at it to the point where they said, "Oh, the clinical trials data are using MADRS, the real-world evidence that you're bringing in from Osmind is using PHQ-9. Now show us that there's equivalence between those scales." So people will say, "Oh, you haven't submitted the NDA yet." Well, okay, we're actively engaged in a scientific conversation with FDA, where we're not under the strict PDUFA clocks of an NDA, but we're looking at the data together. And they're identifying their issues about the data, just like they might do in an NDA process, except we're scientific collaborators in a sense, they don't have to issue a CRL when they have a question.
So in this case, they said, show us that the MADRS and the PHQ-9 are comparable scales, and there's a lot more science than we published in the 10-Q, but we showed you one of the bits of science that we're now submitting to FDA to show them that the PHQ-9 scale used in the 65,000 patients of real-world evidence yields comparable results to the MADRS scale that's used in the clinical trials. So we've been in a very active scientific dialogue with FDA. We don't feel a reason to talk about every stage of that scientific conversation because it doesn't serve anybody. Our objective is drug approval, and we're laser-focused on achieving that.
Thomas Shrader: And a final follow-up. You made a kind of an interesting comment. But for a ketamine-free competitor, they would need stability data to file. Just -- I thought it's an interesting hurdle. How much do they need? And I guess, how much do they need because it's potentially a key.
Jonathan Javitt: Well, under the regs, you're supposed to come in with 2 years of stability data. So if somebody wants to copy us, first of all, they've got to get their hands on a Rommelag blow-fill-seal machine. One of the things that's really turned this whole industry upside down is FDA decided that the competitor, the Weiler machines don't satisfy their sterility requirements. So all of a sudden, there's kind of one place in the world to get these state-of-the-art blow-fill-seal machines. We didn't say it in the conference call, but we've just bought 2 of them. So we've kind of bought out the manufacturing capacity for the short term.
Then they've got to get their hands on a set of molds to make the product that doesn't infringe on our intellectual property. And then they've got to install all of that, validate it at their manufacturing site, which takes half a year to a year. And once they've done all of that, they've got to fill some vials with their product, seal those vials and put them up for 2 years of stability. So sometimes people think patents are what protects you. Sometimes people think that data exclusivity under statute is what protects you. In this case, we estimate that we have a significant manufacturing head start on a lot of people.
Could there be some people out there who are as smart as we are? I sure hope there are because there's a $33 billion sterile injectable products market and clearly won't be us satisfying the whole thing. But is there an extraordinary opportunity to blow away glass, as I said, when's the last time you saw a glass milk bottle on the grocery store shelf.
Operator: The last question comes from Ed Woo with Ascendiant Capital.
Edward Woo: Yes, congratulations on all the progress. Following up your comment about the blow-fill-seal vials. You mentioned that you bought 2 machines. Do you have any exclusivity for those machines in the U.S.? Or is it more limited by the ability of manufacturer to make more machines in the near term?
Jonathan Javitt: Well, Rommelag blow-fill-seal machines get used for a lot of different things, everything from eyedrops that come in little 1 cc vials to IV bottles that are 0.5 liter or a liter. So we don't have any exclusivity on that. Don't expect ever to have exclusivity on that. But in terms of the design of our product, there's a lot about that, that's exclusive to us and our partners at Nephron.
The engineering work underlying this is something that would take somebody else more than a year in our estimate, just to do the engineering work, and they've got to turn that into machining and they've got to get the machine installed, then they've got to start filling and putting up for stability. So we've got a sustainable edge. My wife likes to say that unless you're at the front of the race pack, the view is always the same. So we think we're out front on this. And by the time other people catch up, we'll be upfront with something new. That's who we are.
Edward Woo: I wish you guys good luck.
Operator: There are no more questions at this time. I will now turn the call back to Dr. Javitt for closing remarks. Please go ahead.
Jonathan Javitt: So thank you, operator, and thank all of you for joining us today and for your questions. We're grateful to our shareholders for their continued support, to our employees, our partners, our clinicians for the work that brought us to our first approval. And we're especially grateful to the patients and their families who've given us the real privilege of serving them, of making their lives better and for being part of their families. As always, please reach out to Brian Korb and our Investor Relations team with any further questions. We're available to you any time. Have a great day.
Operator: Thank you. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Before you buy stock in NRx Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and NRx Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*
Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 18, 2026.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.